Immunome, Inc. (IMNM) is a publicly traded Healthcare sector company. As of July 5, 2026, IMNM trades at $23.61 with a market cap of $2.67B and a P/E ratio of -9.92. IMNM moved +9.93% today. Year to date, IMNM is +11.47%; over the trailing twelve months it is +173.58%. Its 52-week range spans $5.15 to $27.65. Analyst consensus is strong buy with an average price target of $35.77. Rallies surfaces IMNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
14 analysts cover IMNM: 0 strong buy, 14 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $35.77.
| Metric | Value |
|---|---|
| Price | $23.61 |
| Market Cap | $2.67B |
| P/E Ratio | -9.92 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.65 |
| 52-Week Low | $5.15 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.01M |
| Net Income | $-224.59M |
| Gross Margin | 0.00% |
14 analysts cover IMNM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.77.